Get the Stockscreener App
1.62
14.08%
0.20
After Hours:
1.61
-0.01
-0.62%
Pacific Biosciences Of California Inc stock is traded at $1.62, with a volume of 13.82M.
It is up +14.08% in the last 24 hours and up +38.46% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.42
Open:
$1.45
24h Volume:
13.82M
Relative Volume:
2.03
Market Cap:
$486.60M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-1.08
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
+6.58%
1M Performance:
+38.46%
6M Performance:
+19.12%
1Y Performance:
-18.18%
1-Day Range:
$1.42
$1.62
1-Week Range:
$1.3735
$1.62
52-Week Range:
$0.8511
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.62 | 426.53M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
131.38 | 230.73B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
94.95 | 141.37B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.92 | 139.39B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.58 | 122.43B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.95 | 43.41B | 5.69B | 1.41B | 577.90M | 6.9828 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Custom strategy builders for tracking Pacific Biosciences of California Inc.Weekly Stock Recap & High Return Stock Watch Alerts - newser.com
Pacific Biosciences Says HiFi Technology Selected for South Korean Pangenome Project - MarketScreener
Why Pacific Biosciences of California Inc. stock is favored by top institutionsQuarterly Performance Summary & High Yield Equity Trading Tips - newser.com
PacBio's HiFi Sequencing Chosen for Korean Pangenome Project - GuruFocus
PacBio HiFi Technology Selected as Core Platform for South Korea’s National Pangenome Project - Yahoo Finance
Can Pacific Biosciences of California Inc. stock resist market sell offs2025 Technical Patterns & Free Community Supported Trade Ideas - newser.com
Statistical indicators supporting Pacific Biosciences of California Inc.’s strengthQuarterly Market Summary & Risk Controlled Stock Pick Alerts - newser.com
Market reaction to Pacific Biosciences of California Inc.’s recent newsMarket Volume Report & AI Enhanced Trading Alerts - newser.com
Analyzing recovery setups for Pacific Biosciences of California Inc. investorsWeekly Gains Report & High Accuracy Trade Signal Alerts - newser.com
Does Pacific Biosciences of California Inc. stock trade at a discount to peersChart Signals & Free Fast Gain Swing Trade Alerts - newser.com
What analysts say about Pacific Biosciences of California Inc stockFundamental Stock Analysis & Small Entry Cost Stocks - earlytimes.in
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now - TradingView
Weiss Ratings Reiterates Sell (E+) Rating for Pacific Biosciences of California (NASDAQ:PACB) - MarketBeat
Detecting price anomalies in Pacific Biosciences of California Inc. with AIEarnings Risk Report & Daily Growth Stock Tips - newser.com
What analysts say about Pacific Biosciences of California Inc P09 stockHealthcare Stock Analysis & Rapid Profit Growth - earlytimes.in
How HiFi sequencing achieves scalable microbial genomics without compromise - PacBio
Forecasting Pacific Biosciences of California Inc. price range with options dataWeekly Investment Recap & Community Verified Trade Alerts - newser.com
Is Pacific Biosciences of California Inc. (P09) stock resilient in recession scenariosIndex Update & Stock Portfolio Risk Management - newser.com
PacBio Stock Dips Despite Announcing Expanded Partnership With seqWell - MSN
Why Is PacBio (PACB) Stock Soaring Today - Yahoo Finance
PacBio (PACB) Technology Chosen for Major Longevity Study - GuruFocus
7,800 Genomes & Epigenomes: PacBio Powers Long Life Family Study with Revio, Q4 2025 Start - Stock Titan
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
PacBio Expands Partnership with seqWell to Distribute LongPlex™ Multiplexing Kit for Enhanced Genomic Sequencing Solutions - Quiver Quantitative
PacBio Expands Partnership with seqWell to Bring Scalable Long Read Sample Prep to More Labs - Yahoo Finance
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today - sharewise.com
Is Pacific Biosciences of California Inc. (P09) stock a buy before new product rollout2025 Breakouts & Breakdowns & Trade Opportunity Analysis Reports - newser.com
Will Pacific Biosciences of California Inc. stock outperform Nasdaq indexJuly 2025 Sector Moves & Reliable Breakout Forecasts - newser.com
Why Pacific Biosciences of California Inc. stock is rated strong buy2025 Year in Review & Long-Term Capital Growth Ideas - newser.com
Is this a good reentry point in Pacific Biosciences of California Inc.July 2025 Closing Moves & AI Powered Buy/Sell Recommendations - newser.com
Will Pacific Biosciences of California Inc. rebound enough to break evenJuly 2025 Earnings & Verified Momentum Watchlists - newser.com
Is Pacific Biosciences of California Inc. a candidate for recovery playJuly 2025 Pullbacks & Pattern Based Trade Signal System - newser.com
Applied Materials, GameStop And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Heatmap analysis for Pacific Biosciences of California Inc. and competitorsWeekly Loss Report & Reliable Price Breakout Alerts - newser.com
Barclays Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $1.5 - 富途牛牛
Can volume confirm reversal in Pacific Biosciences of California Inc.Portfolio Growth Summary & Weekly Breakout Watchlists - newser.com
Can swing trading help recover from Pacific Biosciences of California Inc. losses2025 Historical Comparison & Risk Adjusted Buy and Sell Alerts - newser.com
Powered by PacBio: Selected publications from September 2025 - PacBio
Pacific Biosciences of California, Inc. (NASDAQ:PACB) institutional owners may be pleased with recent gains after 16% loss over the past year - simplywall.st
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):